Differential expression of peroxiredoxin 3 in laryngeal squamous cell carcinoma

This study examined the expression profile of PRDX3 and its possible clinical value in laryngeal squamous cell carcinoma

Hua Zhang; Xuexia Liu; Lei Chen; Li Cai; Ning Li; Peng Zhu; Jian Chen; Xicheng Song; Guojun Li

2016

Head and neck cancer is one of the most malignant carcinomas in the world ; 25% of HNCs are laryngeal carcinomas, and 95-98% of these are laryngeal squamous cell carcinoma
Our results suggest that PRDX3 has substantial clinical impact on the progression of LSCC and shed new light on the role of PRDX3 in treatment resistance and aggressive phenotypes in LSCC
Cellular localization of PRDX3 in LSCC tissues was detected by immunohistochemistry
The role of PRDXs in LSCC is unknown, growing evidence suggests their involvement in HNC progression and oxidative stress resistance
All PRDX proteins were found to be expressed in LSCC tumors and adjacent normal tissues, but PRDX3 was significantly up-regulated in tumor tissues, indicating that it may serve as a promising tumorigenesis-associated protein
Since most chemotherapy or radiotherapy for cancer works through an reactive oxygen species increase and apoptotic induction, our results provide a clue that PRDX3 may be involved in therapy resistance in LSCC
PRDX, peroxiredoxin; LSCC, laryngeal squamous cell carcinoma; Head and neck cancer, head and neck cancer; NSCLC, non-small cell lung cancer; ROS, reactive oxygen species; H2O2, hydrogen peroxide; Tris-buffered saline, tris-buffered saline; IOD, integrated optical density; BSA, bovine serum albumin; Reverse transcription-polymerase chain reaction, reverse transcription-polymerase chain reaction; CCK, cell counting kit

Need more features? Save interactive summary cards to your Scholarcy Library.